SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

21 Jan 2022 Evaluate
The sales moved up 45.00% to Rs. 1170.00 millions for the December 2021 quarter as compared to Rs. 806.91 millions during the year-ago period.The Total revenue for the quarter ended December 2021 of  Rs. 396.39  millions  grew by 152.59% from Rs. 156.93 millions.Operating Profit saw a handsome growth to 438.17 millions from 301.58 millions in the quarter ended December 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202112 202012 % Var
Sales 1170.00 806.91 45.00 1170.00 806.91 45.00 1170.00 806.91 45.00
Other Income 54.42 43.29 25.71 54.42 43.29 25.71 54.42 43.29 25.71
PBIDT 438.17 301.58 45.29 438.17 301.58 45.29 438.17 301.58 45.29
Interest 11.49 8.14 41.15 11.49 8.14 41.15 11.49 8.14 41.15
PBDT 426.68 293.44 45.41 426.68 293.44 45.41 426.68 293.44 45.41
Depreciation 25.99 47.91 -45.75 25.99 47.91 -45.75 25.99 47.91 -45.75
PBT 400.69 245.53 63.19 400.69 245.53 63.19 400.69 245.53 63.19
TAX 4.30 88.60 -95.15 4.30 88.60 -95.15 4.30 88.60 -95.15
Deferred Tax -119.86 3.48 -3544.25 -119.86 3.48 -3544.25 -119.86 3.48 -3544.25
PAT 396.39 156.93 152.59 396.39 156.93 152.59 396.39 156.93 152.59
Equity 160.96 146.37 9.97 160.96 146.37 9.97 160.96 146.37 9.97
PBIDTM(%) 37.45 37.37 0.20 37.45 37.37 0.20 37.45 37.37 0.20

Supriya Lifescience Share Price

628.00 -9.30 (-1.46%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×